Literature DB >> 21118413

Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis.

V Limaye1, P Hakendorf, R J Woodman, P Blumbergs, P Roberts-Thomson.   

Abstract

BACKGROUND: There is a paucity of literature on the patterns and predictors of mortality in idiopathic inflammatory myopathies (IIM). AIMS: To determine the patterns and predictors of mortality in a South Australian cohort of patients with biopsy-proven IIM.
METHODS: The living/deceased status (and for deceased patients the causes of death) of patients with histologically determined IIM was determined from the Births, Deaths and Marriages Registry. Standardised mortality ratios (SMR) were generated compared with the age/gender matched South Australian population. The effect of presence/absence of the components of the Bohan and Peter criteria on risk ratios (RR) for mortality was determined. The effect of comorbidities and autoantibodies on mortality was investigated.
RESULTS: The SMR for mortality in IIM was 1.75 and was significantly increased in all disease subgroups, being highest in patients with dermatomyositis (2.40). Dominant causes of death were cardiovascular disease (31%), infections (22%) and malignancy (11%). Risk factors for death were age at time of biopsy (hazard ratio 1.05), ischaemic heart disease (RR 2.97, P < 0.0001), proximal weakness at diagnosis (RR 1.8, P= 0.03), definite diagnosis of IIM per the Bohan and Peter criteria (RR 2.14, P < 0.0001), and the absence of autoantibodies (RR 1.9, P < 0.001).
CONCLUSIONS: Patients with IIM are at 75% increased risk for mortality, and cardiovascular diseases account for the commonest causes of death. This study suggests a thorough cardiovascular evaluation of these patients is indicated, and raises the possibility that targeted interventions such as the use of aspirin or statins may improve outcomes in IIM.
© 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.

Entities:  

Mesh:

Year:  2012        PMID: 21118413     DOI: 10.1111/j.1445-5994.2010.02406.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  18 in total

Review 1.  Real-world evidence in rheumatic diseases: relevance and lessons learnt.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-02-06       Impact factor: 2.631

Review 2.  [Inflammatory myopathies].

Authors:  Britta Maurer
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

3.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

4.  A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.

Authors:  Sara G Murray; Gabriela Schmajuk; Laura Trupin; Erica Lawson; Matthew Cascino; Jennifer Barton; Mary Margaretten; Patricia P Katz; Edward H Yelin; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

5.  Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Authors:  Adam M Huber; Gulnara Mamyrova; Peter A Lachenbruch; Julia A Lee; James D Katz; Ira N Targoff; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-05       Impact factor: 4.794

6.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

8.  The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis.

Authors:  Vidya Limaye; Colin Luke; Graeme Tucker; Catherine Hill; Susan Lester; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Rheumatol Int       Date:  2012-07-26       Impact factor: 2.631

Review 9.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 10.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.